Literature DB >> 28251374

Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review.

Norio Kubo1,2, Kenichiro Araki3,4, Takahiro Yamanaka1,2, Kouki Hoshino1, Norihiro Ishii1,2, Mariko Tsukagoshi1,2, Takamichi Igarashi1, Akira Watanabe1,2, Keitaro Hirai1, Fumiyoshi Saitoh1,2, Hiroyuki Kuwano2, Ken Shirabe1.   

Abstract

PURPOSE: Interstitial pneumonia (IP) is a progressive and irreversible fibrosis and can be fatal if acute exacerbation (AE) occurs. While a useful risk-scoring system has been established for lung surgery, no risk evaluation exists for AE of IP related to non-pulmonary surgery. The objective of this review is to describe the management for patients with IP.
METHODS: We experienced three hepatectomy cases with IP. The first was a 72-year-old male patient diagnosed with hepatocellular carcinoma. Preoperative computed tomography (CT) revealed IP with reticular shadow at the base of both lungs. After hepatectomy, his IP became acutely exacerbated and did not improve with steroid or sivelestat treatment. The second was a 74-year-old male patient diagnosed with hepatocellular carcinoma, and the third was a 75-year-old male patient with liver metastasis. In both these cases, CT revealed a reticular shadow in the lung fields, with increased serum KL-6 levels. We administered pirfenidone for perioperative management, during which time no respiratory complications occurred.
RESULTS: Perioperative management with pirfenidone for hepatectomy accompanied by IP was successful in our cases.
CONCLUSION: We reviewed reports on the perioperative prevention, intraoperative risk factors, and treatment of postoperative AE of IP and summarized the perioperative management techniques for IP patients undergoing non-pulmonary surgery.

Entities:  

Keywords:  Abdominal surgery; Acute exacerbation; Hepatectomy; Interstitial pneumonia; Pirfenidone

Mesh:

Substances:

Year:  2017        PMID: 28251374     DOI: 10.1007/s00595-017-1489-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  43 in total

1.  Increased intensity of lung infiltrates at the side of lung cancer in patients with lung cancer associated with pulmonary fibrosis.

Authors:  J Fujita; I Yamadori; H Namihira; I Suemitsu; S Bandoh; Y Fukunaga; S Hojo; Y Ueda; N Dobashi; K Dohmoto; J Takahara
Journal:  Lung Cancer       Date:  1999-12       Impact factor: 5.705

2.  Comparisons of financial and short-term outcomes between laparoscopic and open hepatectomy: benefits for patients and hospitals.

Authors:  Yoshikuni Kawaguchi; Yuichiro Otsuka; Hironori Kaneko; Motoki Nagai; Yukihiro Nomura; Mariko Yamamoto; Masahide Otani; Yuichi Ohashi; Kotaro Sugawara; Daisuke Koike; Takashi Ishida; Norihiro Kokudo; Nobutaka Tanaka
Journal:  Surg Today       Date:  2015-05-30       Impact factor: 2.549

3.  Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Keiji Oishi; Yuka Mimura-Kimura; Taku Miyasho; Keisuke Aoe; Yoshiko Ogata; Hideki Katayama; Yoriyuki Murata; Hiroshi Ueoka; Tsuneo Matsumoto; Yusuke Mimura
Journal:  Cytokine       Date:  2012-09-26       Impact factor: 3.861

4.  Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.

Authors:  Takekazu Iwata; Shigetoshi Yoshida; Kaoru Nagato; Takahiro Nakajima; Hidemi Suzuki; Tetsuzo Tagawa; Teruaki Mizobuchi; Satoshi Ota; Yukio Nakatani; Ichiro Yoshino
Journal:  Surg Today       Date:  2014-11-22       Impact factor: 2.549

5.  Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study.

Authors:  Susumu Sakamoto; Sakae Homma; Mingyon Mun; Takeshi Fujii; Atsuko Kurosaki; Kunihiko Yoshimura
Journal:  Intern Med       Date:  2011-01-15       Impact factor: 1.271

6.  Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Susumu Sakamoto; Sakae Homma; Atsushi Miyamoto; Atsuko Kurosaki; Takeshi Fujii; Kunihiko Yoshimura
Journal:  Intern Med       Date:  2010-01-15       Impact factor: 1.271

7.  Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia.

Authors:  Noriyuki Enomoto; Takafumi Suda; Tomohiro Uto; Masato Kato; Yusuke Kaida; Yuichi Ozawa; Hiroo Miyazaki; Shigeki Kuroishi; Dai Hashimoto; Tateaki Naito; Tomoyuki Fujisawa; Takashi Matsui; Naoki Inui; Yutaro Nakamura; June Sato; Tomoaki Mizuguchi; Akihiko Kato; Kingo Chida
Journal:  Respirology       Date:  2008-05       Impact factor: 6.424

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

Review 9.  Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.

Authors:  Francesco Bonella; Susanne Stowasser; Lutz Wollin
Journal:  Drug Des Devel Ther       Date:  2015-12-14       Impact factor: 4.162

10.  Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.

Authors:  Satoshi Ikeda; Akimasa Sekine; Tomohisa Baba; Hideaki Yamakawa; Masato Morita; Hideya Kitamura; Takashi Ogura
Journal:  BMC Pulm Med       Date:  2016-03-03       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.